Beacon Capital Management »

Lineage Cell Therapeutics In shares owned by Beacon Capital Management

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Beacon Capital Management from 13F filings

Historical chart of Beacon Capital Management investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Beacon Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Beacon Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $18k 15k 1.18

More positions owned by Beacon Capital Management

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Vanguard Index Fds Total Stk Mkt (VTI)
Spdr Dow Jones Indl Average Ut Ser 1 (DIA)
Vanguard Admiral Fds 500 Val Idx Fd (VOOV)
Vanguard Index Fds Large Cap Etf (VV)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Vanguard World Mega Grwth Ind (MGK)
Vanguard Index Fds Growth Etf (VUG)
Apple (AAPL)
Vanguard World Fds Inf Tech Etf (VGT)
Amazon (AMZN)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr S&p 500 Grwt Etf (IVW)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)

View all positions for Beacon Capital Management

Top funds holding Lineage Cell Therapeutics In

Vanguard Group
Defender Capital
Raffles Associates
Prescott General Partners
MAI Wealth Advisors
Jpmorgan Chase & Co
Citadel Advisors
Laurion Capital Management
Charles Schwab Investment Management
Bank of New York Mellon
Long Focus Capital Management
Barclays
Royal Bank of Canada
Squarepoint Ops
Jane Street

View all funds holding Lineage Cell Therapeutics In